){kind=logo}
Key Findings in This Issue:
- In an unusual move, the FDA takes issue with the accuracy of Sciecure’s studies in a warning letter over sales promotion material for the company’s sleeping pill
- Office of Inspector General’s 2015 work plan shows agency will examine medical device security, FDA’s regulation
- The Department of Health and Human Services proposes tougher reporting rules in a bid to increase clinical trial transparency
- FDA proposes three studies on direct-to-consumer prescription drug ads in a bid to better understand the impact of ad exposure frequency, spousal influence and risk understanding